Zacks Research Has Positive Outlook of IRWD FY2025 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research lifted their FY2025 EPS estimates for Ironwood Pharmaceuticals in a report released on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $0.31 per share for the year, up from their prior estimate of $0.17. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.20 EPS and FY2026 earnings at $0.35 EPS.

Several other research firms have also weighed in on IRWD. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum decreased their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Ironwood Pharmaceuticals Trading Up 4.2 %

NASDAQ IRWD opened at $2.00 on Monday. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $4.04. Ironwood Pharmaceuticals has a 12 month low of $1.59 and a 12 month high of $15.26. The firm has a market capitalization of $320.06 million, a P/E ratio of -66.67 and a beta of 0.29.

Insider Buying and Selling

In related news, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock valued at $338,591 over the last 90 days. Company insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after purchasing an additional 450,949 shares during the last quarter. State Street Corp increased its holdings in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Ironwood Pharmaceuticals by 5.5% during the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after buying an additional 469,043 shares in the last quarter. Geode Capital Management LLC grew its position in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock worth $14,652,000 after acquiring an additional 13,028 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after acquiring an additional 78,969 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.